Entresto vs Pomalyst
Side-by-side drug price comparison from Medicare Part D data
Verdict
Entresto costs 98% less per claim than Pomalyst ($379.00 vs $17250.00). Neither drug has a generic alternative available. Total Medicare spending: Entresto at $4.8B vs Pomalyst at $3.3B.
| Metric | Entresto | Pomalyst |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $379* | $17,250 |
| Total Medicare Spending Total Medicare Part D spending on this drug | $4.8B | $3.3B |
| Total Claims | 12,560,000 | 192,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | 18.3% | 4.7%* |
| Generic Available | No | No |
| Condition | Heart Failure | Cancer |
| Total Beneficiaries | 1,085,000 | 18,000 |
Entresto costs 98% less per claim than Pomalyst ($379.00 vs $17250.00). Neither drug has a generic alternative available. Total Medicare spending: Entresto at $4.8B vs Pomalyst at $3.3B.
Explore More
Comparing Entresto and Pomalyst on U.S. Medicare prescription-drug pricing requires lining up the underlying CMS Medicare Part D Drug Spending data data side by side. The table above runs the comparison on the canonical fields; the narrative below identifies the factor or factors that drive the most meaningful difference between the two.
Practical use of the comparison: read the data above, then drill into the individual Entresto and Pomalyst detail pages for the underlying breakdown. A pairwise comparison answers the relative question; the per-entity pages answer the absolute question.
Source: CMS Medicare Part D Spending, 2026.